Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 123

1.

Modulation of inflammatory and immune responses by vitamin D.

Colotta F, Jansson B, Bonelli F.

J Autoimmun. 2017 Dec;85:78-97. doi: 10.1016/j.jaut.2017.07.007. Epub 2017 Jul 18. Review.

PMID:
28733125
2.

A low plasma 1,25(OH)2 vitamin D/PTH (1-84) ratio predicts worsening of renal function in patients with chronic heart failure.

Masson S, Barlera S, Colotta F, Magnoli M, Bonelli F, Moro M, Marchioli R, Tavazzi L, Tognoni G, Latini R.

Int J Cardiol. 2016 Dec 1;224:220-225. doi: 10.1016/j.ijcard.2016.09.014. Epub 2016 Sep 10.

PMID:
27657477
3.

Simple, rapid and accurate molecular diagnosis of acute promyelocytic leukemia by loop mediated amplification technology.

Spinelli O, Rambaldi A, Rigo F, Zanghì P, D'Agostini E, Amicarelli G, Colotta F, Divona M, Ciardi C, Coco FL, Minnucci G.

Oncoscience. 2014 Dec 27;2(1):50-8. eCollection 2015.

4.

Targeting the mitotic checkpoint for cancer therapy with NMS-P715, an inhibitor of MPS1 kinase.

Colombo R, Caldarelli M, Mennecozzi M, Giorgini ML, Sola F, Cappella P, Perrera C, Depaolini SR, Rusconi L, Cucchi U, Avanzi N, Bertrand JA, Bossi RT, Pesenti E, Galvani A, Isacchi A, Colotta F, Donati D, Moll J.

Cancer Res. 2010 Dec 15;70(24):10255-64. doi: 10.1158/0008-5472.CAN-10-2101.

5.

Cdc7 kinase inhibitors: 5-heteroaryl-3-carboxamido-2-aryl pyrroles as potential antitumor agents. 1. Lead finding.

Menichincheri M, Albanese C, Alli C, Ballinari D, Bargiotti A, Caldarelli M, Ciavolella A, Cirla A, Colombo M, Colotta F, Croci V, D'Alessio R, D'Anello M, Ermoli A, Fiorentini F, Forte B, Galvani A, Giordano P, Isacchi A, Martina K, Molinari A, Moll JK, Montagnoli A, Orsini P, Orzi F, Pesenti E, Pillan A, Roletto F, Scolaro A, Tatò M, Tibolla M, Valsasina B, Varasi M, Vianello P, Volpi D, Santocanale C, Vanotti E.

J Med Chem. 2010 Oct 28;53(20):7296-315. doi: 10.1021/jm100504d.

PMID:
20873740
6.

Targeting genetic instability in cancer cells.

Colotta F.

Curr Drug Targets. 2010 Oct;11(10):1293-5. No abstract available.

PMID:
20840071
7.

Dual targeting of CDK and tropomyosin receptor kinase families by the oral inhibitor PHA-848125, an agent with broad-spectrum antitumor efficacy.

Albanese C, Alzani R, Amboldi N, Avanzi N, Ballinari D, Brasca MG, Festuccia C, Fiorentini F, Locatelli G, Pastori W, Patton V, Roletto F, Colotta F, Galvani A, Isacchi A, Moll J, Pesenti E, Mercurio C, Ciomei M.

Mol Cancer Ther. 2010 Aug;9(8):2243-54. doi: 10.1158/1535-7163.MCT-10-0190. Epub 2010 Aug 3.

8.

Targeting cell division cycle 7 kinase: a new approach for cancer therapy.

Montagnoli A, Moll J, Colotta F.

Clin Cancer Res. 2010 Sep 15;16(18):4503-8. doi: 10.1158/1078-0432.CCR-10-0185. Epub 2010 Jul 20. Review.

9.

Therapeutic efficacy of the pan-cdk inhibitor PHA-793887 in vitro and in vivo in engraftment and high-burden leukemia models.

Alzani R, Pedrini O, Albanese C, Ceruti R, Casolaro A, Patton V, Colotta F, Rambaldi A, Introna M, Pesenti E, Ciomei M, Golay J.

Exp Hematol. 2010 Apr;38(4):259-269.e2. doi: 10.1016/j.exphem.2010.02.004. Epub 2010 Feb 16.

PMID:
20167248
10.

Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor.

Brasca MG, Amboldi N, Ballinari D, Cameron A, Casale E, Cervi G, Colombo M, Colotta F, Croci V, D'Alessio R, Fiorentini F, Isacchi A, Mercurio C, Moretti W, Panzeri A, Pastori W, Pevarello P, Quartieri F, Roletto F, Traquandi G, Vianello P, Vulpetti A, Ciomei M.

J Med Chem. 2009 Aug 27;52(16):5152-63. doi: 10.1021/jm9006559.

PMID:
19603809
11.

Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability.

Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A.

Carcinogenesis. 2009 Jul;30(7):1073-81. doi: 10.1093/carcin/bgp127. Epub 2009 May 25. Review.

PMID:
19468060
12.

Anticancer drug discovery and development.

Colotta F.

Adv Exp Med Biol. 2008;610:19-42. doi: 10.1007/978-0-387-73898-7_3. Review. No abstract available.

PMID:
18593013
13.

Targeted therapies in cancer: myth or reality? Introduction.

Colotta F, Mantovani A.

Adv Exp Med Biol. 2008;610:v-vi. No abstract available.

PMID:
18593010
14.

Crucial pathophysiological role of CXCR2 in experimental ulcerative colitis in mice.

Buanne P, Di Carlo E, Caputi L, Brandolini L, Mosca M, Cattani F, Pellegrini L, Biordi L, Coletti G, Sorrentino C, Fedele G, Colotta F, Melillo G, Bertini R.

J Leukoc Biol. 2007 Nov;82(5):1239-46. Epub 2007 Jul 26.

PMID:
17656654
15.

Placental growth factor-1 potentiates hematopoietic progenitor cell mobilization induced by granulocyte colony-stimulating factor in mice and nonhuman primates.

Carlo-Stella C, Di Nicola M, Longoni P, Cleris L, Lavazza C, Milani R, Milanesi M, Magni M, Pace V, Colotta F, Avanzini MA, Formelli F, Gianni AM.

Stem Cells. 2007 Jan;25(1):252-61. Epub 2006 Sep 28.

16.
17.

Requirements for the different cysteines in the chemotactic and desensitizing activity of human thioredoxin.

Bizzarri C, Holmgren A, Pekkari K, Chang G, Colotta F, Ghezzi P, Bertini R.

Antioxid Redox Signal. 2005 Sep-Oct;7(9-10):1189-94.

PMID:
16115022
18.

2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors.

Allegretti M, Bertini R, Cesta MC, Bizzarri C, Di Bitondo R, Di Cioccio V, Galliera E, Berdini V, Topai A, Zampella G, Russo V, Di Bello N, Nano G, Nicolini L, Locati M, Fantucci P, Florio S, Colotta F.

J Med Chem. 2005 Jun 30;48(13):4312-31.

PMID:
15974585
19.

Inhibition of the chemokine receptor CXCR2 prevents kidney graft function deterioration due to ischemia/reperfusion.

Cugini D, Azzollini N, Gagliardini E, Cassis P, Bertini R, Colotta F, Noris M, Remuzzi G, Benigni A.

Kidney Int. 2005 May;67(5):1753-61.

20.

Neuroprotection with the CXCL8 inhibitor repertaxin in transient brain ischemia.

Garau A, Bertini R, Colotta F, Casilli F, Bigini P, Cagnotto A, Mennini T, Ghezzi P, Villa P.

Cytokine. 2005 May 7;30(3):125-31.

PMID:
15826819
21.

Inhibition of interleukin-8 (CXCL8/IL-8) responses by repertaxin, a new inhibitor of the chemokine receptors CXCR1 and CXCR2.

Casilli F, Bianchini A, Gloaguen I, Biordi L, Alesse E, Festuccia C, Cavalieri B, Strippoli R, Cervellera MN, Di Bitondo R, Ferretti E, Mainiero F, Bizzarri C, Colotta F, Bertini R.

Biochem Pharmacol. 2005 Feb 1;69(3):385-94. Epub 2004 Dec 9.

PMID:
15652230
22.

Targeting C5a: recent advances in drug discovery.

Allegretti M, Moriconi A, Beccari AR, Di Bitondo R, Bizzarri C, Bertini R, Colotta F.

Curr Med Chem. 2005;12(2):217-36. Review.

PMID:
15638737
23.

Repertaxin, a novel inhibitor of rat CXCR2 function, inhibits inflammatory responses that follow intestinal ischaemia and reperfusion injury.

Souza DG, Bertini R, Vieira AT, Cunha FQ, Poole S, Allegretti M, Colotta F, Teixeira MM.

Br J Pharmacol. 2004 Sep;143(1):132-42. Epub 2004 Aug 9.

24.

Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury.

Bertini R, Allegretti M, Bizzarri C, Moriconi A, Locati M, Zampella G, Cervellera MN, Di Cioccio V, Cesta MC, Galliera E, Martinez FO, Di Bitondo R, Troiani G, Sabbatini V, D'Anniballe G, Anacardio R, Cutrin JC, Cavalieri B, Mainiero F, Strippoli R, Villa P, Di Girolamo M, Martin F, Gentile M, Santoni A, Corda D, Poli G, Mantovani A, Ghezzi P, Colotta F.

Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11791-6. Epub 2004 Jul 28.

25.

IL-8 induces a specific transcriptional profile in human neutrophils: synergism with LPS for IL-1 production.

Martinez FO, Sironi M, Vecchi A, Colotta F, Mantovani A, Locati M.

Eur J Immunol. 2004 Aug;34(8):2286-92.

26.

Key role of proline-rich tyrosine kinase 2 in interleukin-8 (CXCL8/IL-8)-mediated human neutrophil chemotaxis.

Di Cioccio V, Strippoli R, Bizzarri C, Troiani G, Cervellera MN, Gloaguen I, Colagrande A, Cattozzo EM, Pagliei S, Santoni A, Colotta F, Mainiero F, Bertini R.

Immunology. 2004 Apr;111(4):407-15.

27.

IL-1 beta scavenging by the type II IL-1 decoy receptor in human neutrophils.

Bourke E, Cassetti A, Villa A, Fadlon E, Colotta F, Mantovani A.

J Immunol. 2003 Jun 15;170(12):5999-6005.

28.

Isolation of human Fab fragments against ovarian carcinoma using guided selection.

Figini M, Green A, Colotta F, Canevari S.

Methods Mol Biol. 2003;207:145-59. No abstract available.

PMID:
12412473
29.

An HGF-MSP chimera disassociates the trophic properties of scatter factors from their pro-invasive activity.

Michieli P, Cavassa S, Basilico C, De Luca A, Mazzone M, Asti C, Chiusaroli R, Guglielmi M, Bossù P, Colotta F, Caselli G, Comoglio PM.

Nat Biotechnol. 2002 May;20(5):488-95.

PMID:
11981563
30.

Synthesis and immunosuppressive activity of novel prodigiosin derivatives.

D'Alessio R, Bargiotti A, Carlini O, Colotta F, Ferrari M, Gnocchi P, Isetta A, Mongelli N, Motta P, Rossi A, Rossi M, Tibolla M, Vanotti E.

J Med Chem. 2000 Jun 29;43(13):2557-65.

PMID:
10891115
31.

New immunosuppressive drug PNU156804 blocks IL-2-dependent proliferation and NF-kappa B and AP-1 activation.

Mortellaro A, Songia S, Gnocchi P, Ferrari M, Fornasiero C, D'Alessio R, Isetta A, Colotta F, Golay J.

J Immunol. 1999 Jun 15;162(12):7102-9.

32.

Characterization of the new immunosuppressive drug undecylprodigiosin in human lymphocytes: retinoblastoma protein, cyclin-dependent kinase-2, and cyclin-dependent kinase-4 as molecular targets.

Songia S, Mortellaro A, Taverna S, Fornasiero C, Scheiber EA, Erba E, Colotta F, Mantovani A, Isetta AM, Golay J.

J Immunol. 1997 Apr 15;158(8):3987-95.

PMID:
9103470
33.

TNF-alpha, unlike other pro- and anti-inflammatory cytokines, induces rapid release of the IL-1 type II decoy receptor in human myelomonocytic cells.

Orlando S, Matteucci C, Fadlon EJ, Buurman WA, Bardella MT, Colotta F, Introna M, Mantovani A.

J Immunol. 1997 Apr 15;158(8):3861-8.

PMID:
9103454
34.

Regulated expression and release of the IL-1 decoy receptor in human mononuclear phagocytes.

Colotta F, Saccani S, Giri JG, Dower SK, Sims JE, Introna M, Mantovani A.

J Immunol. 1996 Apr 1;156(7):2534-41.

PMID:
8786316
35.

Inhibition of interleukin-1 responsiveness by type II receptor gene transfer: a surface "receptor" with anti-interleukin-1 function.

Re F, Sironi M, Muzio M, Matteucci C, Introna M, Orlando S, Penton-Rol G, Dower SK, Sims JE, Colotta F, Mantovani A.

J Exp Med. 1996 Apr 1;183(4):1841-50.

36.

Reactive oxygen intermediates cause rapid release of the interleukin-1 decoy receptor from human myelomonocytic cells.

Sambo P, Fadlon EJ, Sironi M, Matteucci C, Introna M, Mantovani A, Colotta F.

Blood. 1996 Mar 1;87(5):1682-6.

37.

Production of interleukin-6 by human osteoclast-like cells from giant cell tumor of bone.

Giovannini M, Strippoli P, Serra M, Sironi M, Fincato G, Colotta F, Bonafe M, Biunno I, Mantovani A, Orlandini S, Brandi M, Pastano R, Bagnara G.

Int J Oncol. 1996 Feb;8(2):297-303.

PMID:
21544359
38.

Negative regulators of the interleukin-1 system: receptor antagonists and a decoy receptor.

Mantovani A, Muzio M, Ghezzi P, Colotta F, Introna M.

Int J Clin Lab Res. 1996;26(1):7-14. Review.

PMID:
8739850
39.

Cloning and characterization of a new isoform of the interleukin 1 receptor antagonist.

Muzio M, Polentarutti N, Sironi M, Poli G, De Gioia L, Introna M, Mantovani A, Colotta F.

J Exp Med. 1995 Aug 1;182(2):623-8.

40.

Chemoattractants induce rapid release of the interleukin 1 type II decoy receptor in human polymorphonuclear cells.

Colotta F, Orlando S, Fadlon EJ, Sozzani S, Matteucci C, Mantovani A.

J Exp Med. 1995 Jun 1;181(6):2181-6.

41.

Effects of granulocyte-monocyte colony-stimulating factor (GM-CSF) on expression of adhesion molecules and production of cytokines in blood monocytes and ovarian cancer-associated macrophages.

Bernasconi S, Matteucci C, Sironi M, Conni M, Colotta F, Mosca M, Colombo N, Bonazzi C, Landoni F, Corbetta G, et al.

Int J Cancer. 1995 Jan 27;60(3):300-7.

PMID:
7829234
42.

Cytokine regulation of monocyte recruitment.

Mantovani A, Bottazzi B, Sozzani S, Peri G, Allavena P, Dong QG, Vecchi A, Colotta F.

Arch Immunol Ther Exp (Warsz). 1995;43(2):149-52. Review.

PMID:
8744731
43.

The type II 'decoy' receptor: a novel regulatory pathway for interleukin 1.

Colotta F, Dower SK, Sims JE, Mantovani A.

Immunol Today. 1994 Dec;15(12):562-6. Review.

PMID:
7848516
44.
45.

Inhibition of anchorage-dependent cell spreading triggers apoptosis in cultured human endothelial cells.

Re F, Zanetti A, Sironi M, Polentarutti N, Lanfrancone L, Dejana E, Colotta F.

J Cell Biol. 1994 Oct;127(2):537-46.

46.

Regulation of endothelial and mesothelial cell function by interleukin-13: selective induction of vascular cell adhesion molecule-1 and amplification of interleukin-6 production.

Sironi M, Sciacca FL, Matteucci C, Conni M, Vecchi A, Bernasconi S, Minty A, Caput D, Ferrara P, Colotta F, et al.

Blood. 1994 Sep 15;84(6):1913-21.

47.

Pro- and anti-inflammatory cytokines: interactions with vascular endothelium.

Introna M, Colotta F, Sozzani S, Dejana E, Mantovani A.

Clin Exp Rheumatol. 1994 Sep-Oct;12 Suppl 10:S19-23. Review.

PMID:
7955622
48.

Progressive growth in immunodeficient mice and host cell recruitment by mouse endothelial cells transformed by polyoma middle-sized T antigen: implications for the pathogenesis of opportunistic vascular tumors.

Garlanda C, Parravicini C, Sironi M, De Rossi M, Wainstok de Calmanovici R, Carozzi F, Bussolino F, Colotta F, Mantovani A, Vecchi A.

Proc Natl Acad Sci U S A. 1994 Jul 19;91(15):7291-5.

49.

Vasodilation in multistep paradigm of leucocyte extravasation.

Mantovani A, Colotta F, Sozzani S, Allavena P, Dejana E.

Lancet. 1994 Jun 11;343(8911):1499-500. No abstract available.

PMID:
7911194
50.

The induction of apoptosis is a common feature of the cytotoxic action of ether-linked glycerophospholipids in human leukemic cells.

Diomede L, Piovani B, Re F, Principe P, Colotta F, Modest EJ, Salmona M.

Int J Cancer. 1994 Jun 1;57(5):645-9.

PMID:
8194871

Supplemental Content

Loading ...
Support Center